Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

The stock's fall snapped a five-day winning streak.

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

MWINYI, The First Lady of the Zanzibar Senator, Dr. Rasha Kelej, CEO of Merck Foundation and Chairperson of Merck Foundation Africa Asia Luminary shared, "We are excited to announce the 11th Edition ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

The major European markets are down in negative territory on Friday with investors assessing the likely impact of the monetary policy ...

TANZANIA is set to host the 11th Asia-Africa Luminaries Conference, organised by the Merck Foundation, focusing on health ...